Mupirocin treatment decreased lesional Staphylococcus in patients with cutaneous lupus. Treatment correlated with decreased IFN signaling and inflammatory gene expression, suggesting topical antibiotic could help reduce lupus skin inflammation In A&R https://t.co/lwjnjtSlqC https://t.co/2M7UZVcud7
Topical Mupirocin Treatment Reduces Interferon and Myeloid Signatures in Cutaneous Lupus Erythematous Lesions Through Targeting of Staphylococcus Species.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Dec 2024 – Apr 2025Where it's discussed
-
News10 articles
-
X / Twitter6 posts
-
YouTube2 videos
-
Blogs2 articles
-
Bluesky1 posts
AI synopsis
What people are saying
The overall tone suggests support for the study's conclusions, with posts highlighting how mupirocin reduces bacterial colonization and inflammatory signals, such as interferon activity in lupus skin lesions. Words like 'decreased,' 'correlated,' and phrases like 'could help reduce' reflect optimism but also a cautious acknowledgment of preliminary findings, indicating a moderate level of engagement and perceived impact.
Most discussions clearly support the findings, emphasizing the potential benefits of mupirocin in reducing inflammation and bacterial presence in lupus skin lesions.
While the topic is relevant to lupus treatments, the overall curiosity level appears moderate, with discussions focusing mainly on confirming the results rather than exploring new ideas.
Participants show some engagement by referencing specific effects like decreased IFN signaling and bacterial levels, but the overall depth is moderate, lacking in detailed analysis or discussion.
The posts imply the research could influence future treatment options, though the discussions remain somewhat general and do not fully explore broader clinical or scientific implications.
Abstract in brief
- Topical mupirocin treatment effectively reduces Staphylococcus colonization in CLE skin lesions, leading to a decrease in interferon signaling and inflammation.
- The study found that lowering Staphylococcus levels with mupirocin also decreased monocyte presence and improved skin barrier function in CLE lesions.
- Using a simple antibiotic like mupirocin could be a promising approach to manage skin inflammation in lupus by targeting bacterial infections that exacerbate the immune response.]
Top posts
Most liked on X and BlueskyMupirocin treatment decreased lesional Staphylococcus in patients with cutaneous lupus. Treatment correlated with decreased IFN signaling and inflammatory gene expression, suggesting topical antibiotic could help reduce lupus skin inflammation In A&R doi.org/10.1002/art.... #Medsky #Dermsky
Weekly recap in ACR journals Topical mupirocin treatment for lesional Staphylococcus in cutaneous lupus erythematous https://t.co/lwjnjtSlqC Frailty measure agreement in systemic lupus erythematosus https://t.co/5YFwOU9Dwd Heart failure incidence in patients with and without https://t.co/WhTAE7W575
RT @ACR_Journals: Weekly recap in ACR journals Topical mupirocin treatment for lesional Staphylococcus in cutaneous lupus erythematous ht…
RT @ACR_Journals: Mupirocin treatment decreased lesional Staphylococcus in patients with cutaneous lupus. Treatment correlated with decreas…
RT @ACR_Journals: Weekly recap in ACR journals Topical mupirocin treatment for lesional Staphylococcus in cutaneous lupus erythematous ht…
All mentions
Mupirocin Reduces Inflammation in Cutaneous Lupus by Targeting Bacteria
Mupirocin decreases Staphylococcus aureus colonization in skin lesions, reducing inflammatory markers, interferon gene expression, and monocyte levels, offering a potential approach to managing inflammation in cutaneous…
Mupirocin May Reduce Inflammation in Cutaneous Lupus
Recent research indicates that mupirocin reduces Staphylococcus aureus colonization in lupus skin lesions, decreasing inflammation, interferon signaling, and monocyte levels, offering a promising management approach for…
RT @ACR_Journals: Weekly recap in ACR journals Topical mupirocin treatment for lesional Staphylococcus in cutaneous lupus erythematous ht…
Topical mupirocin effectively reduces inflammation in cutaneous lupus by targeting Staphylococcus and lowering interferon signaling. by Abernathy-Close L, Mears J (...) Kahlenberg JM et 7 al. in Arthritis Rheumatol https://t.co/PIgiztZxC5 #MedX #MedResearch
RT @ACR_Journals: Weekly recap in ACR journals Topical mupirocin treatment for lesional Staphylococcus in cutaneous lupus erythematous ht…
Weekly recap in ACR journals Topical mupirocin treatment for lesional Staphylococcus in cutaneous lupus erythematous https://t.co/lwjnjtSlqC Frailty measure agreement in systemic lupus erythematosus https://t.co/5YFwOU9Dwd Heart failure incidence in patients with and without https://t.co/WhTAE7W575
RT @ACR_Journals: Mupirocin treatment decreased lesional Staphylococcus in patients with cutaneous lupus. Treatment correlated with decreas…
Mupirocin treatment decreased lesional Staphylococcus in patients with cutaneous lupus. Treatment correlated with decreased IFN signaling and inflammatory gene expression, suggesting topical antibiotic could help reduce lupus skin inflammation In A&R https://t.co/lwjnjtSlqC https://t.co/2M7UZVcud7
Mupirocin treatment decreased lesional Staphylococcus in patients with cutaneous lupus. Treatment correlated with decreased IFN signaling and inflammatory gene expression, suggesting topical antibiotic could help reduce lupus skin inflammation In A&R doi.org/10.1002/art.... #Medsky #Dermsky
AJ
AR
PM
F
SR